Qi Hua, Chairman of Sainuote Bio, Confirms Participation in the 2nd International Medical Device Innovation Summit and Files IPO Prospectus

“Hosted by the People's Government of Gaochun District, organized by the Science and Technology Bureau of Gaochun District and VCBeat, and co-organized by Jiangsu Gaochun High-Tech Industrial Development Zone, this event aims to further analyze the innovative transformation and development of China's medical device industry, gain insights into development trends, and promote the integration of industry and capital.The 2nd International Summit on Medical Device Innovation"will be held onJuly 28, 2020AtNanjing · GaochunHosted.

Qi Hua, Chairman of Sinocell Bio, Confirms Attendance at the 2nd International Summit on Medical Device Innovation

Qi Hua,Chairman of the Board, Sainote Biotech

Qi Hua, a senior engineer and graduate of Henan Medical University, is an Outstanding Entrepreneur of Zhengzhou City. In 2010, he founded Henan Sinoit Biotechnology Co., Ltd. After a decade of dedication, the company has grown into a conglomerate comprising Sinoit Technologies (USA), Sinoit Instruments (Shenzhen), Sinoit Diagnostics (Zhengzhou), and Zhengzhou Sanhe Trading. This expansion has established a comprehensive industry chain strategy for its tumor pathology product portfolio.

Sinotest Biology has been successively recognized as a National High-Tech Enterprise, Henan Provincial Enterprise Technology Center, Zhengzhou Innovative Leading Team, Henan Provincial Postdoctoral Research Station for Pathological Diagnosis, Henan Provincial Engineering Technology Research Center for Tumor Pathological Diagnostic Reagents, and Zhengzhou Academician Workstation for Precision Diagnosis of Tumor Pathology.

In addition to the research and development of cutting-edge technologies, the number of approved products under Sinocelltech continues to reach new highs.Today, Sanote’s products have been adopted by numerous renowned Grade A tertiary hospitals and leading clinical testing institutions across China, including Southwest Hospital of Army Medical University, the First Affiliated Hospital of Zhejiang University School of Medicine, Ningbo Pathology Center, Tongji Hospital, the Second Xiangya Hospital, Henan Cancer Hospital, Jiangxi Cancer Hospital, and KingMed Diagnostics.    

In recent years, as a strategic emerging industry prioritized by the Chinese government, the medical device sector has enjoyed robust policy support—ranging from deepened reforms in review and approval processes, innovation in high-value consumables, Diagnosis-Related Groups (DRG), Supply, Processing, and Distribution (SPD) systems, to medical consortiums, tiered diagnosis and treatment models, and the Marketing Authorization Holder (MAH) system for medical devices. This has fueled rapid growth in the industry. According to statistics, China’s medical device market size reached RMB 628.5 billion in 2019 and is projected to exceed RMB 900 billion by 2022.

The 2nd International Summit on Medical Device Innovationwill be2020 Medical Device Innovation Vitality Listleveraging the release as an opportunity to deeply focus onGenetic Testing, In Vitro Diagnosticsand other hot topics, gathering the most active medical device innovators, listed companies, financial institutions, and healthcare providers from China and abroad to create a premier event for the medical device industryOfflineGrand Event.

Future Trends: Four 2020 Medical Device Innovation Vitality Lists Released On-Site

Four Hot Tracks in the Medical Device Sector Are Preferred, with Four Major Segments Carefully Selected: Chemiluminescence, Home Medical Devices, Orthopedic Implants, and Cutting-Edge Tech Products. Who Are the 2020 Innovative Vitality Enterprises in the Medical Device Industry?At the 2020 Second International Summit on Medical Device Innovation, the 2020 Medical Device Innovation Vitality Rankings will be released. Witness the unveiling of four ranking lists and discover which 40 companies emerge as the most innovative.

Featured Guests: Over 18 Medical Device Industry Leaders to Engage in Dialogue with You

Yuan-Ting Zhang, Academician of the International Academy of Medical and Biological Engineering, and Jie Tian, Director of the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, will join forces with NMPA medical device review experts, founders of leading innovative medical device companies, forward-looking medtech investors, and senior department directors to discuss the future of medical devices. More guests are being confirmed; stay tuned.

Confirmed Speakers (Partial):

Zhang Yuanting, Academician of the International Academy of Medical and Biological Engineering, IEEE Fellow, Fellow of the American Institute for Medical and Biological Engineering

Tian Jie, Director of the Key Laboratory of Molecular Imaging, Chinese Academy of Sciences

Bao Ningzhong, Professor at Nanjing Tech University

Dong Yansheng, NMPA Medical Device Review Expert

Ding Haibo, Founder and CEO of Beden Medical

Sun Qi, Founding Managing Partner of DaoTong Capital

Zhao Xiangwei, Deputy Dean of the School of Biological Science and Medical Engineering, Southeast University

Yang Song, Chief Analyst of the Pharmaceutical Industry at Cinda Securities

Wu Hanliang, Director of the Strategy Department, Guotai Junan Securities

Wang Yaqi, Co-founder and Chairman of Raybiotech

Du Zhengping, Co-founder of Aoran Biotech    

Zhou Quan, Managing Director at Legend Capital

Qi Hua, Chairman of Sinotech Biology

Guo Yan, Director of the Hengdao Pathology Diagnosis Center

Li Gang, Founder of Changjiang Biotech

More guests to be confirmed...

In-Depth Coverage: Two Roundtables Focus on Industry Trends and the Development Direction of In Vitro Diagnostics

In recent years, domestic medical device innovation has risen rapidly. The primary market has seen the emergence of unicorn companies such as United Imaging Healthcare, Venus Medtech, and MicroPort CardioFlow. In the secondary market, Mindray Medical’s market capitalization has exceeded RMB 300 billion, while Chunli Medical’s stock price has surged more than tenfold over two years. By segment, China’s in vitro diagnostics (IVD) market reached RMB 60.4 billion in 2018, representing an 18.4% year-on-year growth. It is projected to maintain an annual growth rate of approximately 18%, making China one of the fastest-growing IVD markets globally.

All these signs seem to herald the arrival of a golden age for domestically produced medical devices. What trends will shape the future development of China’s medical device industry? Which sub-sectors within the domestic medical device market hold greater promise? The morning session of this summit will feature a roundtable discussion focusing onMedical Devices in the Post-Pandemic EraDevelopment opportunities; the afternoon roundtable session will delve into specialized subfields,andVeteran Investors in the IVD Industry: Precision Dialogue with High-Quality Innovative Enterprises。